New Test Detects TB and Antibiotic Resistance

FRIDAY, July 26 (HealthDay News) -- A new test to detect bacteria that cause tuberculosis and simultaneously determine if the bacteria are resistant to the antibiotic rifampin has been approved by the U.S. Food and Drug Administration.

The Xpert MTB/RIF Assay is less complex to administer than other screening tests for TB. Results are available in about two hours, while traditional methods to detect TB could take up to several months, the agency said in a news release.

People with weakened immune systems are most likely to develop full-blown TB once infected with the disease-causing bacteria, the FDA said. TB is a leading killer globally of people with HIV/AIDS.

Common symptoms of TB include a severe cough lasting at least three weeks, chest pain, coughing up blood, fatigue and weight loss, the agency said.

The test is manufactured and marketed by Cepheid, based in Sunnyvale, Calif.

More information

The U.S. Centers for Disease Control and Prevention has more about TB.

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.